Research & Development Mekonos closes $25M funding round for cell therapy platform

Mekonos closes $25M funding round for cell therapy platform


Mekonos closes funding of $25M in a series a round as it develops the future of cell therapies on a chip. The Biotech Company has developed a platform that is able to support the multiple delivery of cell payloads right down to the cell level, and allows for the physical delivery of these payloads.

Biotech Startup Mekonos raises oversubscribed $25 million after prominent research labs had promising results for the company’s developed platform for chip technology. The delivery system for the payload will be ex-vivo.

As Mekonos closes funding it has revealed plans for the use of this acquired capital. The company is planning to venture into business development, Microfluidics, MEMS among other areas.

The future of cell therapies on a chip shows the excellent ability to provide repeated and measured doses, such as CRISPR, into vulnerable cell types that include stem cells.

With this latest funding, Mekonos plans to bring change to cell therapy, an area that has not witnessed innovation in over two decades. Mekonos official stated that they are keen on disrupting existing technology in cell engineering and are making an effort to delve into personalized medicine on a large scale.

+ posts

Latest news

Novo Nordisk Set to Slash Victoza Production to Boost Ozempic Supply

In response to the escalating demand for its GLP-1 weight loss products, Novo Nordisk is adopting a...

Merck to Purchase Caraway Therapeutics For Over $600M

Merck & Co. has openly expressed its continuous pursuit of acquisitions, and currently, the prominent pharmaceutical company...

NanoString Faces Setback in Patent Infringement Case Against Genomics

In a recent legal skirmish in the biotechnology sector, NanoString finds itself on the losing end of...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you